Biotechnology

Overview

Our prominent Life Science and Biotechnology group has been an icon in Patent Prosecution for almost 30 years. With our extensive background in Life Science disciplines, our patent powerhouse is comprised of 20+ attorneys (the majority with M.Sc., and Ph.D., graduate degrees) who embody an array of experience and are highly integrated with the firm’s corporate, litigation, and transactional practices. Our impressive track record includes valued scientists, skilled engineers, accomplished patent agents and highly-respected attorneys.

We provide a vast range of experience with global pharmaceutical and biotechnology IP related procedures, patent filings, and regulatory requirements. Clients benefit from our significant knowledge in pharmaceutical, biotechnology, medical device global patent post-grant proceedings and litigation. We have been responsible for developing and implementing global IP patent procurement strategies for FDA approved medicines, IP strategic planning, studies on patentability, infringement and validity, IP audits and due diligence, licensing and technology transfer.  Our patent attorneys routinely provide valued services including freedom to operate and competitor analyses for a wide range of pharmaceutical and biotechnology small and large molecule drug therapies. In addition, we deliver value through the support of our teams’ patent agents, technology specialists, paralegals, specialists, and our broad range of IP services to contain costs.  We strive to exceed our client’s expectations in client-service standards, communication, and proficient results.

In 2016 and 2019, Honigman was highly recognized as an Intellectual Property “Firm to Watch” by LMG Life Sciences Awards.